Skip to main content

Articles

Page 9 of 35

  1. Understanding the treatment needs of patients with dementia with Lewy bodies (DLB) is essential to develop treatment strategies. We examined the treatment needs of patients with DLB and their caregivers and th...

    Authors: Mamoru Hashimoto, Yuta Manabe, Takuhiro Yamaguchi, Shunji Toya and Manabu Ikeda
    Citation: Alzheimer's Research & Therapy 2022 14:188
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:4

  2. Granulovacuolar degeneration bodies (GVBs) are intracellular vesicular structures that commonly accompany pathological tau accumulations in neurons of patients with tauopathies. Recently, we developed the firs...

    Authors: Marta Jorge-Oliva, Jasper F. M. Smits, Vera I. Wiersma, Jeroen J. M. Hoozemans and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:187
    Content type: Research Published on:

  3. Alzheimer’s disease has become one of the most common neurodegenerative diseases worldwide, which seriously affects the health of the elderly. Early detection and intervention are the most effective prevention...

    Authors: Qin Yang, Xin Li, Xinyun Ding, Feiyang Xu and Zhenhua Ling
    Citation: Alzheimer's Research & Therapy 2022 14:186
    Content type: Review Published on:

  4. To investigate the characteristics and associations of MRI-visible perivascular spaces (PVS) with clinical progression and longitudinal cognitive decline across the Alzheimer’s disease spectrum.

    Authors: Ming-Liang Wang, Qiao-Qiao Zou, Zheng Sun, Xiao-Er Wei, Peng-Yang Li, Xue Wu and Yue-Hua Li
    Citation: Alzheimer's Research & Therapy 2022 14:185
    Content type: Research Published on:

  5. Growing evidence has showed an association between habitual glucosamine use and type 2 diabetes (T2D). However, the effect of habitual glucosamine use on risk of dementia remains poorly understood. Our study a...

    Authors: Chenjie Xu, Yabing Hou, Xuexian Fang, Hongxi Yang and Zhi Cao
    Citation: Alzheimer's Research & Therapy 2022 14:184
    Content type: Research Published on:

  6. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide and remains without effective cure. Increasing evidence is supporting the mitochondrial cascade hypothesis, proposing that los...

    Authors: Christina F. de Veij Mestdagh, Frank Koopmans, Jonathan C. Breiter, Jaap A. Timmerman, Pieter C. Vogelaar, Guido Krenning, Huibert D. Mansvelder, August B. Smit, Robert H. Henning and Ronald E. van Kesteren
    Citation: Alzheimer's Research & Therapy 2022 14:183
    Content type: Research Published on:

  7. Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-mont...

    Authors: Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer and Donald A. Berry
    Citation: Alzheimer's Research & Therapy 2022 14:182
    Content type: Research Published on:

  8. Neuronal- and astrocyte-derived exosomes have been identified as an optimal source for screening biomarkers for Alzheimer’s disease (AD). However, few studies focus on the bulk exosome population isolated from...

    Authors: Huimin Cai, Yana Pang, Qi Wang, Wei Qin, Cuibai Wei, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei and Longfei Jia
    Citation: Alzheimer's Research & Therapy 2022 14:181
    Content type: Research Published on:

  9. Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy t...

    Authors: Fadi Rofo, Nicole G. Metzendorf, Cristina Saubi, Laura Suominen, Ana Godec, Dag Sehlin, Stina Syvänen and Greta Hultqvist
    Citation: Alzheimer's Research & Therapy 2022 14:180
    Content type: Research Published on:

  10. Synaptic degeneration is an early event closely associated with the course of Alzheimer’s disease (AD). The identification of synaptic blood biomarkers is, therefore, of great interest and clinical relevance. ...

    Authors: Pablo Mohaupt, Marie-Laure Pons, Jérôme Vialaret, Constance Delaby, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2022 14:179
    Content type: Mini Review Published on:

  11. This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). A...

    Authors: Randall J. Bateman, Jeffrey Cummings, Scott Schobel, Stephen Salloway, Bruno Vellas, Mercè Boada, Sandra E. Black, Kaj Blennow, Paulo Fontoura, Gregory Klein, Sheila Seleri Assunção, Janice Smith and Rachelle S. Doody
    Citation: Alzheimer's Research & Therapy 2022 14:178
    Content type: Review Published on:

  12. Aggregated amyloid-β (Aβ) is considered a pathogenic initiator of Alzheimer’s disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. ...

    Authors: Hee Yang Lee, Soljee Yoon, Jeong Hwa Lee, Keunwan Park, Youngeun Jung, Illhwan Cho, Donghee Lee, Jisu Shin, Kyeonghwan Kim, Sunmi Kim, Jimin Kim, Koeun Kim, Seung Hoon Han, Seong Muk Kim, Hye Ju Kim, Hye Yun Kim…
    Citation: Alzheimer's Research & Therapy 2022 14:177
    Content type: Research Published on:

  13. Individuals with Down syndrome (DS) are increasingly eligible for clinical trial intervention, particularly for the treatment or prevention of Alzheimer disease (AD). Yet, little is known about research attitu...

    Authors: Ira T. Lott, Katharine A. Kirby, Eric Doran and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2022 14:176
    Content type: Research Published on:

  14. Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer’s disease (AD). However, studies investigating the differential diagn...

    Authors: Steffen Halbgebauer, Petra Steinacker, Daniel Riedel, Patrick Oeckl, Sarah Anderl-Straub, Jolina Lombardi, Christine A. F. von Arnim, Magdalena Nagl, Armin Giese, Albert C. Ludolph and Markus Otto
    Citation: Alzheimer's Research & Therapy 2022 14:175
    Content type: Research Published on:

  15. Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer’s disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer’s disease...

    Authors: Eric B. Dammer, Lingyan Ping, Duc M. Duong, Erica S. Modeste, Nicholas T. Seyfried, James J. Lah, Allan I. Levey and Erik C. B. Johnson
    Citation: Alzheimer's Research & Therapy 2022 14:174
    Content type: Research Published on:

  16. The enrollment into clinical trials of persons at risk for autosomal dominant Alzheimer’s disease (ADAD) in whom the onset of disease can be accurately predicted facilitates the interpretation of outcomes (e.g...

    Authors: Angélica Zuno-Reyes, Esmeralda Matute, Karin Ernstrom, Mellissa Withers, Yaneth Rodriguez-Agudelo, Rema Raman and John M. Ringman
    Citation: Alzheimer's Research & Therapy 2022 14:173
    Content type: Research Published on:

  17. The recent promise of disease-modifying therapies for Alzheimer’s disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the d...

    Authors: Edward N. Wilson, Christina B. Young, Javier Ramos Benitez, Michelle S. Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, Nandita M. Kasireddy, Marian Shahid, Nicole K. Corso, Qian Wang, Gabriel Kennedy, Alexandra N. Trelle, Betty Lind, Divya Channappa, Malia Belnap…
    Citation: Alzheimer's Research & Therapy 2022 14:172
    Content type: Research Published on:

  18. The effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer’s disease (AD) have been previously evidenced. To complete the economic analysis, there is a need to assess whether socie...

    Authors: Javier Mar, Oliver Ibarrondo, Igor Larrañaga, Lorea Mar-Barrutia and Myriam Soto-Gordoa
    Citation: Alzheimer's Research & Therapy 2022 14:171
    Content type: Research Published on:

  19. Early diagnosis of mild cognitive impairment (MCI) is essential for timely treatment planning. With recent advances in the wearable technology, interest has increasingly shifted toward computer-aided self-diag...

    Authors: Kyeonggu Lee, Kang-Min Choi, Seonghun Park, Seung-Hwan Lee and Chang-Hwan Im
    Citation: Alzheimer's Research & Therapy 2022 14:170
    Content type: Research Published on:

  20. Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacologica...

    Authors: John T. O’Brien, Leonidas Chouliaras, Janet Sultana, John-Paul Taylor and Clive Ballard
    Citation: Alzheimer's Research & Therapy 2022 14:169
    Content type: Review Published on:

  22. Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD ...

    Authors: Blanca Rodríguez-Fernández, Natalia Vilor-Tejedor, Eider M. Arenaza-Urquijo, Gonzalo Sánchez-Benavides, Marc Suárez-Calvet, Grégory Operto, Carolina Minguillón, Karine Fauria, Gwendlyn Kollmorgen, Ivonne Suridjan, Manuel Castro de Moura, David Piñeyro, Manel Esteller, Kaj Blennow, Henrik Zetterberg, Immaculata De Vivo…
    Citation: Alzheimer's Research & Therapy 2022 14:167
    Content type: Research Published on:

  23. Tau-PET is a prognostic marker for cognitive decline in Alzheimer’s disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau-PET may allow precision-medicine predic...

    Authors: Davina Biel, Ying Luan, Matthias Brendel, Paul Hager, Anna Dewenter, Alexis Moscoso, Diana Otero Svaldi, Ixavier A. Higgins, Michael Pontecorvo, Sebastian Römer, Anna Steward, Anna Rubinski, Lukai Zheng, Michael Schöll, Sergey Shcherbinin, Michael Ewers…
    Citation: Alzheimer's Research & Therapy 2022 14:166
    Content type: Research Published on:

  24. Blood adiponectin and leptin are adipokines that emerged as potential biomarkers for predicting Alzheimer’s disease (AD) owing to their strong connection with obesity. Although obesity affects the relation bet...

    Authors: Keun You Kim, Junghee Ha, Minae Kim, So Yeon Cho, Hyunjeong Kim and Eosu Kim
    Citation: Alzheimer's Research & Therapy 2022 14:165
    Content type: Research Published on:

  25. Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics.

    Authors: José Viña, Joaquín Escudero, Miquel Baquero, Mónica Cebrián, Juan Antonio Carbonell-Asíns, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Meléndez, José Ferrer-Rebolleda, Mª del Puig Cózar-Santiago, Jose Manuel Santabárbara-Gómez, Mariona Jové, Reinald Pamplona, Francisco José Tarazona-Santabalbina and Consuelo Borrás
    Citation: Alzheimer's Research & Therapy 2022 14:164
    Content type: Research Published on:

  26. Obstructive sleep apnoea (OSA) is the most frequent form of sleep-disordered breathing in patients with Alzheimer’s disease (AD). Available evidence demonstrates that both conditions are independently associat...

    Authors: Farida Dakterzada, Iván D. Benítez, Adriano Targa, Anna Carnes, Montse Pujol, Mariona Jové, Olga Mínguez, Rafi Vaca, Manuel Sánchez-de-la-Torre, Ferran Barbé, Reinald Pamplona and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2022 14:163
    Content type: Research Published on:

  27. Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biom...

    Authors: Keun You Kim, Jaesub Park, Yong Hyu Jeong, Hyun Jeong Kim, Eun Lee, Jin Young Park, Eosu Kim and Woo Jung Kim
    Citation: Alzheimer's Research & Therapy 2022 14:162
    Content type: Research Published on:

  28. The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients.

    Authors: Matthew Paul Lennol, Irene Sánchez-Domínguez, Inmaculada Cuchillo-Ibañez, Elena Camporesi, Gunnar Brinkmalm, Daniel Alcolea, Juan Fortea, Alberto Lleó, Guadalupe Soria, Fernando Aguado, Henrik Zetterberg, Kaj Blennow and Javier Sáez-Valero
    Citation: Alzheimer's Research & Therapy 2022 14:161
    Content type: Research Published on:

  29. Studies have reported higher plasma matrix metalloproteinase-9 (MMP-9) levels in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Despite evidence that MMP-9 activity and its influence on AD patho...

    Authors: Amaryllis A. Tsiknia, Erin E. Sundermann, Emilie T. Reas, Steven D. Edland, James B. Brewer, Douglas Galasko and Sarah J. Banks
    Citation: Alzheimer's Research & Therapy 2022 14:160
    Content type: Research Published on:

  30. Carefully conducted systematic reviews (SRs) can provide reliable evidence on the effectiveness of treatment strategies for Alzheimer’s disease (AD). Nevertheless, the reliability of SR results can be limited ...

    Authors: Claire C. W. Zhong, Jinglun Zhao, Charlene H. L. Wong, Irene X. Y. Wu, Chen Mao, Jerry W. F. Yeung and Vincent C. H. Chung
    Citation: Alzheimer's Research & Therapy 2022 14:159
    Content type: Research Published on:

  31. Microglia are the resident immune cells found in our brain. They have a critical role in brain maintenance. Microglia constantly scavenge various waste materials in the brain including damaged or apoptotic neu...

    Authors: Kyung Won Jo, Dohyun Lee, Dong Gon Cha, Eunji Oh, Yoon Ha Choi, Somi Kim, Eun Seo Park, Jong Kyoung Kim and Kyong-Tai Kim
    Citation: Alzheimer's Research & Therapy 2022 14:158
    Content type: Research Published on:

  32. The standard Centiloid (CL) method was proposed to harmonize and quantify global 18F-labeled amyloid beta (Aβ) PET ligands using MRI as an anatomical reference. However, there is need for harmonizing and quantify...

    Authors: Soo-Jong Kim, Hongki Ham, Yu Hyun Park, Yeong Sim Choe, Young Ju Kim, Hyemin Jang, Duk L. Na, Hee Jin Kim, Seung Hwan Moon and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2022 14:157
    Content type: Research Published on:

  33. The incidence of cognitive impairment is increasing with an aging population. Developing effective strategies is essential to prevent dementia. Higher education level is associated with better baseline cogniti...

    Authors: Yue Wang, Shinan Wang, Wanlin Zhu, Na Liang, Chen Zhang, Yuankun Pei, Qing Wang, Shiping Li and Jiong Shi
    Citation: Alzheimer's Research & Therapy 2022 14:156
    Content type: Research Published on:

  34. In the last decade, non-invasive blood-based and neurophysiological biomarkers have shown great potential for the discrimination of several neurodegenerative disorders. However, in the clinical workup of patie...

    Authors: Alberto Benussi, Valentina Cantoni, Jasmine Rivolta, Silvana Archetti, Anna Micheli, Nicholas Ashton, Henrik Zetterberg, Kaj Blennow and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2022 14:155
    Content type: Research Published on:

  35. Considerable overlap exists between the risk factors of dementia and cerebral small vessel disease (SVD). However, studies remain limited to older cohorts wherein pathologies of both dementia (e.g. amyloid) an...

    Authors: Audrey Low, Maria A. Prats-Sedano, Elizabeth McKiernan, Stephen F. Carter, James D. Stefaniak, Stefania Nannoni, Li Su, Maria-Eleni Dounavi, Graciela Muniz-Terrera, Karen Ritchie, Brian Lawlor, Lorina Naci, Paresh Malhotra, Clare Mackay, Ivan Koychev, Craig W. Ritchie…
    Citation: Alzheimer's Research & Therapy 2022 14:154
    Content type: Research Published on:

  36. Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate the...

    Authors: Simone Baiardi, Corinne Quadalti, Angela Mammana, Sofia Dellavalle, Corrado Zenesini, Luisa Sambati, Roberta Pantieri, Barbara Polischi, Luciano Romano, Matteo Suffritti, Giuseppe Mario Bentivenga, Vanda Randi, Michelangelo Stanzani-Maserati, Sabina Capellari and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2022 14:153
    Content type: Research Published on:

  37. Chronic neuroinflammation is one of the hallmarks of late-onset Alzheimer’s disease (AD) dementia pathogenesis. Carrying the apolipoprotein ε4 (APOE4) allele has been associated with an accentuated response to br...

    Authors: Brandon Ebright, Isaac Assante, Roy A. Poblete, Shaowei Wang, Marlon V. Duro, David A. Bennett, Zoe Arvanitakis, Stan G. Louie and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2022 14:152
    Content type: Research Published on:

  38. Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with various clinical and neuropathological subtypes. The two major pathological proteins accumulating in the brains of FTD patien...

    Authors: Kasper Katisko, Nadine Huber, Tarja Kokkola, Päivi Hartikainen, Johanna Krüger, Anna-Leena Heikkinen, Veera Paananen, Ville Leinonen, Ville E. Korhonen, Seppo Helisalmi, Sanna-Kaisa Herukka, Valentina Cantoni, Yasmine Gadola, Silvana Archetti, Anne M. Remes, Annakaisa Haapasalo…
    Citation: Alzheimer's Research & Therapy 2022 14:151
    Content type: Research Published on:

  39. PPARγ agonists have been proven to be neuroprotective in vitro and in vivo models of Alzheimer’s disease (AD). In the present study, we identified ligustrazine piperazine derivative (LPD) as a novel PPARγ agon...

    Authors: Zongyang Li, Xiangbao Meng, Guoxu Ma, Wenlan Liu, Weiping Li, Qian Cai, Sicen Wang, Guodong Huang and Yuan Zhang
    Citation: Alzheimer's Research & Therapy 2022 14:150
    Content type: Research Published on:

  40. Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of g...

    Authors: Jan Traub, Markus Otto, Roxane Sell, Dennis Göpfert, György Homola, Petra Steinacker, Patrick Oeckl, Caroline Morbach, Stefan Frantz, Mirko Pham, Stefan Störk, Guido Stoll and Anna Frey
    Citation: Alzheimer's Research & Therapy 2022 14:149
    Content type: Research Published on:

  41. Imbalanced synaptic transmission appears to be an early driver in Alzheimer’s disease (AD) leading to brain network alterations. Early detection of altered synaptic transmission and insight into mechanisms cau...

    Authors: Monica van den Berg, Mohit H. Adhikari, Marlies Verschuuren, Isabel Pintelon, Tamara Vasilkovska, Johan Van Audekerke, Stephan Missault, Loran Heymans, Peter Ponsaerts, Winnok H. De Vos, Annemie Van der Linden, Georgios A. Keliris and Marleen Verhoye
    Citation: Alzheimer's Research & Therapy 2022 14:148
    Content type: Research Published on:

  42. Resting heart rate (RHR) has been linked with an increased risk of dementia. However, evidence characterizing the associations of RHR with different dementia subtypes and their underlying mechanisms remains sc...

    Authors: Yue-Ting Deng, Kevin Kuo, Bang-Sheng Wu, Ya-Nan Ou, Liu Yang, Ya-Ru Zhang, Shu-Yi Huang, Shi-Dong Chen, Yu Guo, Rui-Qi Zhang, Lan Tan, Qiang Dong, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:147
    Content type: Research Published on:

  43. Previous studies found that cancer survivors had a reduced risk of dementia compared with the general population. However, these findings were uncertain because of survivor bias and a lack of stratification by...

    Authors: Dan-Dan Zhang, Ya-Nan Ou, Liu Yang, Ya-Hui Ma, Lan Tan, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:146
    Content type: Research Published on:

  44. The relationship of specific body composition in the thighs and brain amyloid-beta (Aβ) deposition remained unclear, although there were growing evidence that higher muscle and fat mass in thighs had a protect...

    Authors: Sung Hoon Kang, Kyung Hyun Lee, Yoosoo Chang, Yeong Sim Choe, Jun Pyo Kim, Hyemin Jang, Hee Young Shin, Hee Jin Kim, Seong-Beom Koh, Duk L. Na, Sang Won Seo and Mira Kang
    Citation: Alzheimer's Research & Therapy 2022 14:145
    Content type: Research Published on:

  45. Cortical atrophy is associated with cognitive decline, but the association is not perfect. We aimed to identify factors explaining the discrepancy between the degree of cortical atrophy and cognitive decline i...

    Authors: Anna Linnéa Svenningsson, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson and Rik Ossenkoppele
    Citation: Alzheimer's Research & Therapy 2022 14:144
    Content type: Research Published on:

  46. The protracted preclinical stage of Alzheimer’s disease (AD) provides the opportunity for early intervention to prevent the disease; however, the lack of minimally invasive and easily detectable biomarkers and...

    Authors: Kohei Yuyama, Hui Sun, Yasuyuki Igarashi, Kenji Monde, Takumi Hirase, Masato Nakayama and Yoichi Makino
    Citation: Alzheimer's Research & Therapy 2022 14:140
    Content type: Research Published on:

  47. An active lifestyle is associated with improved cognitive functions in aged people and may prevent or slow down the progression of various neurodegenerative diseases including Alzheimer’s disease (AD). To inve...

    Authors: Jogender Mehla, Scott H. Deibel, Hadil Karem, Shakhawat Hossain, Sean G. Lacoursiere, Robert J. Sutherland, Majid H. Mohajerani and Robert J. McDonald
    Citation: Alzheimer's Research & Therapy 2022 14:143
    Content type: Research Published on:

  48. The individual and complementary value of the Visual Short-Term Memory Binding Test (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) as markers to trace the AD continuum was investigated. It was...

    Authors: Mario A. Parra, Clara Calia, Vivek Pattan and Sergio Della Sala
    Citation: Alzheimer's Research & Therapy 2022 14:142
    Content type: Research Published on:

  49. Both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA) are related to cognitive impairment and dementia. This study aimed to clarify CAA- and HA-related small vessel disease (SVD) imaging ma...

    Authors: Ting-Bin Chen, Wei-Ju Lee, Jun-Peng Chen, Shiang-Yu Chang, Chun-Fu Lin and Hung-Chieh Chen
    Citation: Alzheimer's Research & Therapy 2022 14:141
    Content type: Research Published on:

  50. In Alzheimer’s disease (AD), fibrillar tau initially occurs locally and progresses preferentially between closely connected regions. However, the underlying sources of regional vulnerability to tau pathology r...

    Authors: Anna Rubinski, Nicolai Franzmeier, Anna Dewenter, Ying Luan, Ruben Smith, Olof Strandberg, Rik Ossenkoppele, Martin Dichgans, Oskar Hansson and Michael Ewers
    Citation: Alzheimer's Research & Therapy 2022 14:139
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193